Blood ClotsSymptoms, Doctors, Treatments, Advances & More
Learn About Blood Clots
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Emory Hemophilia Of Georgia
Christine Kempton is a Hematologist practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 29 years. Dr. Kempton is rated as an Elite provider by MediFind in the treatment of Blood Clots. She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, Von Willebrand Disease (VWD), and Bone Marrow Aspiration. Dr. Kempton is board certified in American Board Of Internal Medicine, 2004.
Atrium Health Levine Cancer Institute
Ruben Mesa is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Mesa is rated as an Elite provider by MediFind in the treatment of Blood Clots. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is board certified in American Board Of Internal Medicine, Hematology. Dr. Mesa is currently accepting new patients.
Doris Quon is a Hematologist practicing medicine in Los Angeles, California. Dr. Quon is rated as an Elite provider by MediFind in the treatment of Blood Clots. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, and Hemophilic Arthropathy. Dr. Quon is currently accepting new patients.
Summary: This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to \<12 years) who have severe hemophilia A or B, with or without inhibitory antibodies to FVIII or FIX. Number of participants: Approximately 85 participants will be enrolled into the study: * Approximately 60 fitusi...
Summary: This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.